Osteoarthritis research in 2017 provided new insights into the long-term effects of intra-articular glucocorticoids, and also led to the approval of a novel, longer-lasting glucocorticoid formulation. New drugs for the treatment of osteoarthritis also emerged this year, including a small-molecule inhibitor of the Wnt signalling pathway.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Flexion Therapeutics Inc. Zilretta (triamcinolone acetonide extended-release injectable suspension), for intra-articular use [label] Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208845s000lbl.pdf (2017).
McAlindon, T. E. et al. Effect of intra-articular triamcinolone versus saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967–1975 (2017).
Yazici, Y. et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 25, 1598–1606 (2017).
McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363–388 (2014).
Bodick, N. et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J. Bone Joint Surg. Am. 97, 877–888 (2015).
Conaghan, P. G. et al. Phase 2b trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intra-articular injection in knee osteoarthritis. Arthritis Rheumatol. 10.1002/art.40364 (2017).
Cicuttini, F. M. et al. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann. Rheum. Dis. 63, 1124–1127 (2004).
Nielsen, F. K., et al. Risk factors for joint replacement in knee osteoarthritis; a 15-year follow-up study. BMC Musculoskelet. Disord. 18, 510 (2017).
Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26, 18–27 (2018).
Bannuru, R. R. et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163, 365–372 (2015).
The work of T.E.M. is supported by the NIH. The work of R.R.B. is supported by the NIH National Center for Complementary and Integrative Health (NCCIH). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NCCIH.
T.E.M. declares that he has acted as a consultant for Flexion Therapeutics and as an Advisory Board member for Samumed. R.R.B. declares no competing interests.
About this article
Cite this article
McAlindon, T., Bannuru, R. Latest advances in the management of knee OA. Nat Rev Rheumatol 14, 73–74 (2018). https://doi.org/10.1038/nrrheum.2017.219
Journal of Orthopaedic Surgery and Research (2021)
lncRNA FER1L4 is dysregulated in osteoarthritis and regulates IL-6 expression in human chondrocyte cells
Scientific Reports (2021)